Mediators of Inflammation

Mediators of Inflammation / 2016 / Article

Research Article | Open Access

Volume 2016 |Article ID 5359768 | 10 pages |

Serotonin-Exacerbated DSS-Induced Colitis Is Associated with Increase in MMP-3 and MMP-9 Expression in the Mouse Colon

Academic Editor: Mirella Giovarelli
Received03 Mar 2016
Revised24 Apr 2016
Accepted29 May 2016
Published05 Jul 2016


Background. 5-HT enhances dextran sulfate sodium- (DSS-) induced colitis and is involved in inflammatory bowel disease (IBD). Matrix metalloproteinases (MMPs) play roles in the process of intestinal inflammation. Aims. To examine whether 5-HT induces MMPs expression in mouse colon to enhance DSS-induced colitis. Materials and Methods. C57BL/6J (B6) mice were treated with either low-dose (1.0 mg/kg) or high-dose (2.0 mg/kg) 5-HT by enema, low-dose (1.0%) or high-dose (2.5%) DSS, or combined low-dose (1.0%) DSS and (1.0 mg/kg) 5-HT. Mouse colitis was analyzed. MMPs and tissue inhibitors of MMPs (TIMPs) mRNA were measured by real-time quantitative RT-PCR in mouse colon and in human Caco-2 cells and neutrophils. MMP-3 and MMP-9 protein levels were quantified from immunohistochemistry (IHC) images of mouse colons. Results. 5-HT exacerbated DSS-induced colitis, low-dose 5-HT induces both MMP-3 and MMP-9, and high-dose 5-HT only increased MMP-3 mRNA expression in mouse colon. Mouse colon MMP-3 and MMP-9 protein levels were also elevated by 5-HT treatment. The MMP-2, TIMP-1, and TIMP-2 mRNA levels were increased in the inflamed colon. 5-HT induced MMP-3 and MMP-9 mRNA expression in Caco-2 and human neutrophils, respectively, in vitro. Conclusion. 5-HT induced MMP-3 and MMP-9 expression in mouse colon; these elevated MMPs may contribute to DSS-induced colitis.

1. Introduction

The inflammatory bowel disease (IBD), comprised of ulcerative colitis (UC) and Crohn’s disease (CD), is the recurrent chronic idiopathic inflammatory disease of the GI tract [13]. Although the precise etiology of IBD remains unknown, a variety of inflammatory mediators and enzymes, such as cytokines, growth factors, reactive oxygen species (ROS), GI hormones, and matrix metalloproteinases (MMPs), are known to regulate inflammation and are involved in pathogenesis of IBD [4, 5].

5-Hydroxytryptamine (5-HT, serotonin), a monoamine neurotransmitter, is biochemically derived from tryptophan. Tryptophan hydroxylase (TPH) is a rate-limiting enzyme in the synthesis of 5-HT and is located prominently in enterochromaffin (EC) cells [6]. Approximately 90% of 5-HT in humans is synthesized in gastrointestinal (GI) EC cells by tryptophan hydroxylase-1 (TPH1) [7], and 5% of 5-HT is synthesized in myenteric neurons [8] and brain by TPH2 [9]. 5-HT is an important mucosal regulatory molecule, which mediates gut motility and secretary functions, promotes growth and turnover of mucosal epithelium, and maintains intestinal homeostasis [10]. 5-HT is also a neuron transmitter in the central nervous system to regulate mood and cause vasoconstriction [10, 11]. In the intestinal mucosa, the serotonin reuptake transporter (SERT) takes up 5-HT into epithelial cells and serotonergic neurons and inactivates it [12]. 5-HT exerts its functions by binding to 5-HT receptors which are widely expressed in intestinal tissues [13, 14]. 5-HT is involved in the pathogenesis of intestinal disorders, including IBD [1517] and irritable bowel syndrome [15, 18, 19]. The immunomodulatory effects of 5-HT are associated with gut inflammation [11]. The changes in EC cell numbers and 5-HT contents in colon mucosa of IBD patients have been reported [15, 20]. Mice treated with dextran sulfate sodium (DSS) to induce colitis also have increased 5-HT levels contributed by higher number of EC cells and decreased SERT mRNA expression [21]. 5-HT also exacerbated trinitrobenzene sulfonic acid- (TNBS-) induced mouse colitis and is believed to play a key role in pathogenesis of experimental colitis [22, 23].

MMPs are a class of structurally related zinc- and calcium-dependent enzymes, which are responsible for the metabolism of extracellular matrix (ECM) via the remodeling degradation of most components of the ECM [24, 25]. To date, 23 distinct MMPs have been identified in humans (24 in mice) [26]. MMPs facilitate cell migration and cell infiltration through degradation of basement membrane and ECM [24, 27]. MMPs catalyze proteolytic cleavage of biologically active protein molecules, such as cytokines, growth factors, and chemokines, from a membrane-anchored inactive form into a free active form to maintain tissue homeostasis. Under physiological conditions, MMPs are secreted as a latent form of enzyme at low levels and are conversed to active enzymes by proteolytic cleavage [28]. The MMP proteins are tightly controlled at multiple levels, including transcription, translation, secretion, and activation [25, 26]. Additionally, MMP proteins are also regulated by tissue inhibitors of MMPs (TIMPs), which are endogenous inhibitors of MMPs. TIMPs consist of four members, TIMP-1, TIMP-2, TIMP-3, and TIMP-4, all of which regulate MMP activities by forming a 1 : 1 complex with the high zinc binding site of MMPs. TIMPs are important regulators of tissue remodeling and cellular behavior [29, 30].

In active IBD, many MMPs and TIMPs, including MMP-2, MMP-3, and MMP-9 and TIMP-1 and TIMP-2 were elevated in the flamed tissues compared to the noninflamed tissue [3133]. MMP-2 (gelatinase A) and MMP-9 (gelatinase B) are able to proteolytically degrade gelatin. Under physiological condition MMP-2 is ubiquitously expressed [26]. MMP-2 appears to be protective against DSS-, TNBS-, and Salmonella typhimurium-induced colitis [34]. MMP-9 is mainly secreted from inflammatory cells, such as neutrophils, monocytes, and macrophages and specially degrades basement membrane type IV collagen, as well as other ECM components [27, 35]. Of the MMPs, MMP-9 is the most abundantly expressed in inflamed tissues of IBD patients [33]. MMP-3 (stromelysin-1) is secreted by epithelial cells, fibroblasts, vascular smooth cells, endothelial cells, and macrophages [26, 3639]. MMP-3 degrades ECM components such as fibronectin, denatured collagens (gelatin), laminin, and proteoglycans [26]. Both MMP-3 and MMP-9 are believed to be involved in the process of IBD pathology [40, 41]. Proinflammatory cytokines, such as IL-6, IL-8, and TNF-α, can induce the transcription, translation, and secretion of MMPs [32, 42, 43].

DSS-induced colitis is an animal colitis model resembling ulcerative colitis. Although the mechanism by which DSS induces colitis is not clear, DSS damaged colon epithelium is highly relevant to human colitis [44]. It has been shown that DSS increases MMP-2, MMP-3, and MMP-9 mRNA levels in colon [45, 46]. In this study, we explored whether 5-HT exacerbated DSS-induced colitis can be contributed by MMPs expression in the colon.

2. Material and Methods

2.1. Animal Studies

C57BL/6J (B6) mice purchased from Vital River Laboratory Animal Technology Co. Ltd. (Beijing, China) were maintained in ventilated cages with free access to food and water. Mice were fed with rodent chow from Beijing HFK Bioscience Co. Ltd. (Beijing, China). Animal Care and Use Committee in the hospital approved all procedures in this study.

Male mice, at 6–8 weeks of age, with body weight of 20–25 g, were divided into 6 groups treated with 5-HT (MW 212.68, Sigma, St Louis, USA, Cat. number H9523) or DSS (MW 36–50 kDa, MP Biomedicals, Santa Ana, USA, Cat. number 160110). These are (i) low-dose (1.0 mg/kg) 5-HT () and (ii) high-dose (2.0 mg/kg) 5-HT (), both groups receiving 5-HT in saline by enema at days 1 and 4 [22]; (iii) low-dose (1%) DSS () and (iv) high-dose (2.5%) DSS (), both groups receiving DSS in drinking water for 5 days; (v) DSS + 5-HT (), mice being treated with 1.0% DSS and 1 mg/kg 5-HT concurrently; (vi) control group (), mice receiving enema with saline. Mice were monitored daily for body weight and signs of colitis, including diarrhea and perianal ulceration to obtain disease activity index (DAI). Mice were euthanized at day six.

After euthanasia, the colon length was measured, and the sera were collected. The colon tissue was washed in PBS, and then half was fixed in 10% formalin and embedded in paraffin. Sections were stained by hematoxylin and eosin (H&E) for pathological examination or by immunohistochemistry (IHC). The other half of colon was stored at −80°C for RNA extraction. RNAlater (Qiagen, Hilden, Germany) was used immediately when the samples were collected to prevent RNA degradation. The severity of colitis was evaluated by microscopic examination of colon tissues. Each mouse was scored for inflammation and pathology in a blinded fashion using a modified system as we described previously [47]. These include lymphocytes and neutrophil infiltration (0–3 points), Paneth cell and goblet cell degranulation (0–2 points), epithelium reactivity such as crypt distortion (0–3 points), and inflammatory foci (0–3 points). The threshold for detection of severe acute inflammation corresponds to scores of 6 in this study.

2.2. Immunohistochemical (IHC) Staining

Four-micron sections of paraffin-embedded samples were mounted on poly-L-lysine-coated slides. IHC was performed using a modified biotin-peroxidase complex method as described previously [31]. Sections were then incubated overnight with a rabbit polyclonal antibody for MMP-3 (1 : 100, Abcam, London, England, Cat. number ab52915). The antigen-antibody complex was detected with biotinylated goat anti-rabbit antibody (1 : 300, ZSBio com, Beijing, China, Cat. number PV-9000) after hybridized with streptavidin-HRP, which was visualized by reacting with 3,3-diaminobenzidine. MMP-9 was detected by a goat polyclonal antibody (1 : 100 dilution, Santa Cruz, CA, USA, Cat. number sc-6840) as primary antibody and secondary antibody was a biotinylated rabbit anti-goat antibody (1 : 300 dilution, Boster Biological Technology Co. Ltd, Wuhan, China, Cat. number SA1023). The sections were counterstained with hematoxylin. The negative control sections were obtained by omitting the primary antibody or using an unrelated rabbit polyclonal antibody.

The MMP-3 and MMP-9 protein levels were evaluated by a blind way in 10 fields under 400x magnification from each slide. One hundred cells per field were categorized as follows: “−”, 0%, no staining; “+”, >25% of cells were stained; “++”, 26 to 50% of cells were stained; and “+++”, >50% of cells were stained.

2.3. Quantitative Real-Time PCR (qPCR)

qPCR was performed as we described previously [31]. Briefly, total RNA was extracted using TRIzol Reagent (Invitrogen, USA) according to the manufacturer’s instruction. The cDNA was synthesized using PrimeScript RT Master Mix (Takara, Japan). The primer sequences for human and mouse samples (Table 1) were designed with Primer3.0 [48] and the primers were synthesized by Sangon Biotechnology (Zhengzhou, China). The reaction mixture of real-time qPCR was performed using a CFX96 Real-Time PCR system (BIO-RAD, USA), and the cyber green was used to detect PCR products. When the primers annealing temperature was 60°C or more, a two-step PCR reaction method was used. When the primers annealing temperature was below 60°C, a three-step method was used. Each sample was assayed in triplicate. The efficiency of PCR amplification was 97% to 105%. A melting curve analysis was performed for the PCR products of each target gene and β-actin to evaluate primer specificity. The relative abundance of target gene mRNA level was evaluated using the comparative Ct () method and was normalized to -actin mRNA level. The mRNA expression level was presented by the relative fold by comparing the quantity of mRNA in different groups. When the Ct value is higher than 35, the gene is considered as unexpressed.

SpeciesmRNAGenePrimer sequenceAmplicon (bp)


M: mouse, H: human.
2.4. Cell Culture

Caco-2, a human colon enterocyte-like cell line (ATCC), was cultured at 37°C in an atmosphere of 5% CO2 and maintained in high-glucose DMEM supplemented with 2 mM glutamine, 100 U/mL penicillin, 100 μg/mL streptomycin, 1% nonessential amino acids, and 10% heat-inactivated fetal bovine serum (FBS) (Hyclone, Utah, USA). For 5-HT stimulation experiments, cells were seeded in 12-well plates at a density of 1.25 104 cells/well. The cells were serum-starved for 24 h before adding 5-HT to minimize the effect of 5-HT present in the FBS. 5-HT was added to the serum-free medium at different concentrations for up to 24 h.

Heparinized blood samples were collected from consented healthy volunteers. The blood samples were seeded in 6-well plates at a volume of 1.5 mL/well of DMEM and were stimulated with 10 μM 5-HT for 24 h. Leucocytes were isolated from the wells by the addition of erythrocyte lysis buffer, containing 0.16 M NH4Cl, 10 mM KHCO3, and 0.01 mM K2-EDTA (pH 7.4) at 4°C. The lysate was transferred into a 15 mL centrifuge tube and centrifuged at 1500 rpm, 4°C for 5 min to pellet leucocytes, which were immediately processed for RNA isolation and determination of MMP-9 mRNA levels.

2.5. Statistical Analysis

Student’s -test, one-way analysis of variance (ANOVA), and Mann-Whitney test were used to compare the data from different groups. The significant difference was defined as . Data was reported as means ± standard deviations (SD). All statistical analysis was performed by using the SPSS 19.0 statistics package (SPSS Inc., Chicago, IL, USA).

3. Results

3.1. 5-HT Exaggerated DSS-Induced Colitis

Similar to Regmi’s study that 5-HT exaggerated TNBS-induced colitis, we found 5-HT also exacerbated DSS-induced colitis [22] (Table 2, Figures 1 and 2). 5-HT alone, at either low (1.0 mg/kg) or high (2.0 mg/kg) dosage, did not induce colitis determined by DAI and histopathological analysis. Mice treated with 1% DSS had signs of mild colitis, including diarrhea and loss of body weight shown at day 5, but the weight loss was less than 10% at day 6. Mild inflammation was seen in colon tissue sections, including increased infiltration of inflammatory cells in the mucosa and submucosa, mild crypt distortion, and shortened crypt depth. Mice drinking 2.5% DSS suffered severe colitis, diarrhea, bloody stools, and losing 21% of body weight at day six. Mice receiving both 1% DSS and 1 mg/kg 5-HT had a similar extent of colitis as those receiving high-dose DSS. The shortened colon was associated with the increased DAI. The pathological analysis demonstrated severe inflammation, including ulcerative lesions, increased number of infiltrating inflammatory cells, crypt loss, and erosion of the mucosa and submucosa.

GroupControl1 mg 5-HT2 mg 5-HT1% DSS1% DSS + 1 mg 5-HT2.5% DSS

Change of BW (%)2.1 ± 2.41.8 ± 1.80.9 ± 3.3−5.9 ± 4.2−19.0 ± 5.9−21.6 ± 5.9
Colon length (cm)7.8 ± 0.57.6 ± 0.37.4 ± 0.46.4 ± 0.65.2 ± 0.74.9 ± 0.5
Colon H&E staining scores0.1 ± 0.10.3 ± 0.10.4 ± 0.26.3 ± 0.910.7 ± 2.511.6 ± 1.9

Change of BW presents the change of mouse body weight at day 6.
P < 0.05 versus control mice.

While 5-HT alone did not induce colitis, high-dose 5-HT significantly increased the levels of proinflammatory cytokine IL-6 and chemokine IL-8 mRNA in the colons (Table 3). DSS alone strongly induced IL-6 mRNA and TNF-α, but not IL-8 mRNA levels. Combined 1% DSS and 1 mg/kg 5-HT treatment produced the same pattern of cytokine/chemokine expression as the DSS treatment, that is, no induction of IL-8 mRNA levels.

GroupControl1 mg 5-HT2 mg 5-HT1% DSS1% DSS + 1 mg 5-HT2.5% DSS

IL-61 ± 0.11.4 ± 0.32.6 ± 0.6144 ± 24.21722 ± 415.91070 ± 445.1
IL-81 ± 0.41.3 ± 0.33.7 ± 0.60.9 ± 0.11.8 ± 0.051.1 ± 0.1
TNF-α1 ± 0.21.5 ± 0.11.7 ± 0.35.6 ± 0.88.5 ± 1.69.8 ± 1.2

P < 0.05 versus control mice.
The data stands for relative fold of cytokine mRNA.
3.2. 5-HT Increased MMP-3 and MMP-9, but Not MMP-2, TIMP-1, and TIMP-2, mRNA Levels in Mouse Colon

MMPs play an important role in tissue modeling and damage in IBD [31, 41], and the proteolytic activity of MMPs is tightly regulated by their natural inhibitors, TIMPs [29, 30]; we explored whether MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 mRNA expressions are induced by 5-HT in mouse colons. We found that 5-HT alone increased both MMP-3 and MMP-9 mRNA levels; low-dose and high-dose 5-HT increased MMP-3 mRNA by 2- and 4-fold, respectively (Figure 3). Low-dose 5-HT also induced MMP-9 mRNA by 5.5-fold, although high-dose 5-HT did not increase MMP-9 mRNA levels significantly. Contrary to MMP-3 and MMP-9 mRNA expressions, 5-HT alone did not affect MMP-2, TIMP-1, and TIMP-2 mRNA expression.

Consistent with the literature, DSS-treated colons had elevated expression of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 mRNAs with the exception of TIMP-2 mRNA in low-dose DSS-treated colon (Table 4). Induction of MMP-2 and TIMP-2 by DSS and DSS + 5-HT was rather modest; MMP-2 was increased 1.8- to 6.3-fold and TIMP-2 was increased 3.8- to 6.0-fold. Induction of MMP-3, MMP-9, and TIMP-1 reached 2-log higher in mice treated with either DSS + 5-HT or high-dose DSS compared with the control mice.

GroupControl1% DSS1% DSS + 1 mg 5-HT2.5% DSS

MMP-21.0 ± 0.041.8 ± 0.22.9 ± 0.26.3 ± 0.3
MMP-31.0 ± 0.0528.1 ± 12.2218 ± 101.5170 ± 37
MMP-91.0 ± 0.0611.8 ± 2.052.7 ± 9.6111.4 ± 19.8
TIMP-11.0 ± 0.039.8 ± 3.5114.6 ± 27.382.1 ± 10.7
TIMP-21.0 ± 0.031.2 ± 0.26.0 ± 1.93.8 ± 0.5

P < 0.05 versus control mice.
The data presents 8 mice of each group and stands for relative fold.
3.3. 5-HT Increased MMP-3 and MMP-9 Protein Levels in Mouse Colon Analyzed by IHC

We performed MMP-3 IHC and found that MMP-3 was located at epithelial cells, endothelial cells, and some infiltrating cells in the lamina propria (Figure 4, top panels). We quantified the protein levels based on the number of positively stained cells in the field. Consistent with gene expression, the MMP-3 protein levels were elevated 3.7-fold in the colons of mice treated with high-dose 5-HT, although the smaller increase of MMP-3 protein in mice treated with low-dose 5-HT is not significantly higher than the control mice (Table 5).

GroupnControl1 mg 5-HT2 mg 5-HT1% DSS1% DSS + 1 mg 5-HT2.5% DSS

MMP-360.5 ± 0.50.8 ± 1.03.7 ± 0.85.7 ± 2.08.8 ± 2.08.2 ± 3.8
MMP-960.3 ± 0.53.0 ± 1.10.7 ± 0.84.2 ± 1.09.0 ± 2.77.5 ± 4.2

P < 0.05 versus control mice; P < 0.05 versus 1 mg 5-HT group for MMP-3 or versus 2 mg 5-HT group for MMP-9.

MMP-9 was expressed mainly in the infiltrating inflammatory cells (Figure 4, lower panels). Similar to the mRNA expression pattern, MMP-9 protein was elevated in the colons of mice treated with low-dose, but not high-dose, 5-HT. As expected, the colons of DSS-treated mice had nearly 10-fold higher MMP-3 and MMP-9 proteins than the control colons (Table 5).

3.4. 5-HT Increases MMP-3 in Caco-2 Cells and MMP-9 mRNA in Leucocytes

Since MMP-3 is expression in colon epithelial cells and MMP-9 is mainly synthesized in leucocytes [26, 35], we tested the direct effect of 5-HT on the expression MMP-3 in Caco-2 cells and MMP-9 mRNA in leucocytes. In Caco-2 cells, 5-HT significantly increased the MMP-3 mRNA levels after 24 h treatment with either 5 or 10 μM 5-HT compared to the control cells (Figure 5(a)). MMP-9 mRNA level was not changed under the same conditions (data not shown). MMP-9 mRNA level in leucocytes was also increased 6-fold after 24 h treatment with 10 μM 5-HT (Figure 5(b)). No MMP-3 mRNA was detected in leucocytes (data not shown).

4. Discussion

5-HT is involved in pathogenesis of IBD [1517] and is well documented to exacerbate chemical-induced colitis in mice [22, 23]. The development of IBD is associated with changes of EC cells [49, 50]. The elevated EC cell number and decreased SERT mRNA expression lead to increase in 5-HT content, which is associated with the pathogenesis of DSS-induced colitis [21]. Since MMPs are upregulated in IBD and other inflammatory conditions and DSS treatment induced MMP-2, MMP-3, and MMP-9 mRNA levels in mouse colon [45, 46], we analyzed the direct effect of 5-HT on the expression of these MMP genes. We found 5-HT alone induced MMP-3 and MMP-9 but not MMP-2 gene expression in the colon. Furthermore, we showed the direct effect of 5-HT induction of MMP-3 expression in Caco-2 cells and MMP-9 expression in leucocytes. Thus, we provided the first evidence to show that 5-HT has a direct effect on the induction of MMPs in two different cell types.

5-HT-induced MMP-3 and MMP-9 gene expression may be mediated by induction of proinflammatory cytokines, since IL-6 and IL-8 mRNA levels are significantly elevated in the colons of mice treated with high-dose 5-HT. Induction of the same proinflammatory cytokines is in rat colons after being treated by 1.0 mg/kg 5-HT [22]. These 5-HT activated cytokines and chemokine are produced by local neutrophils, monocytes/macrophages, dendritic cells, and T cells [5153] and are known to induce MMP-3 expression [37, 38]. MMP-9 is predominantly synthesized in inflammatory cells, and the consequence of MMP-9 induction draws more leukocytes from the circulation to colon mucosa to worsen inflammation [54]. Furthermore, MMP-9 can potentiate IL-8 activity tenfold, further enhancing the chemokine activity [55]. Therefore, mice treated with combined 5-HT and low-dose DSS could produce as severe colitis as mice treated with high-dose DSS.

We noted that the expression of MMP-9 in gene and protein was no longer increased in the colons of mice treated with high-dose 5-HT in spite of having high levels of IL-6, IL-8, and TNF-α expression. It suggested that there is a dose-effect of 5-HT on MMP-9 expression. Apparently there is a negative feedback mechanism between MMP-9 protein and 5-HT biosynthesis, since in Mmp9−/− mice, the TPH1 gene expression is highly regulated [56]. Therefore, the high level of 5-HT inhibits further induction of MMP-9 gene, although the exact mechanism is unknown.

While MMP-2 has the same function with that of MMP-9 in proteolytical degradation of gelatin, the expression of MMP-2 is ubiquitous and constitutive under physiological conditions [25, 26]. The expression of MMP-2 does not respond to inflammatory stimuli because MMP-2 gene lacks the binding site for inflammatory transcription factor [26]. It is possible that the high basal level of MMP-2 expression makes it more difficult to detect a low level of induction by 5-HT. This point is supported by the smaller fold of induction in DSS-treated colons; MMP-2 gene was induced 1.8- to 6.3-fold, whereas MMP-3 was induced 28- to 218-fold, and MMP-9 was 11- to 111-fold. Although we did not test the function of MMPs analyzed in this study, we suspect the elevated expression of MMP-9 aids, while MMP-2 suppresses inflammation as illustrated by several groups [57, 58]. The function of MMP-3 is less clear in the colon.

5-HT did not affect TIMP-1 and TIMP-2 gene expression, although DSS-induced strong inflammation induced both TIMP gene expressions. The similar pattern of induction of TIMPs and MMPs has been reported for IBD patients [59]. It was reported that the ratio of MMP-3/TIMP-1 is increased in inflamed colons compared with noninflamed colon tissues of IBD patients [60]. The results from human and animal model indicate that MMPs and TIMPs are involved in the process of inflammation and their expressions are regulated by multifactor and multistep, and cytokines and growth factors are involved in expression regulation of both MMPs and TIMPs [30, 61].

Judging from the higher fold of induction for TIMP-1 (10- to 115-fold) than TIMP-2 (3.8- to 6.0-fold) and the fold of induction of MMP-2 and MMP-9, it is consistent with the notion that MMP-2 is primarily inhibited by TIMP-2 while MMP-9 is mainly inhibited by TIMP-1 [62, 63]. In IBD patients after the remission of intestinal inflammation by Infliximab, a chimeric monoclonal anti-TNF-α antibody, the upregulated MMPs and TIMPs, including MMP-2, MMP-3, and MMP-9 and TIMP-1 and TIMP-2, were recessed [59]. Besides inhibition of MMPs, TIMPs have many other functions such as regulation of cell proliferation, cell migration, angiogenesis, and apoptosis [29].

5. Conclusion

Our findings show that 5-HT induces the expression of MMP-3 and MMP-9 in mouse colon. This is a direct effect since 5-HT induces MMP-3 mRNA levels in human colon cancer Caco-2 cells and MMP-9 mRNA in human primary culture of leucocytes. Our results support the notion that 5-HT exacerbates DSS-induced colitis by enhancing the production of MMP-3 and MMP-9. The significance of our findings is that we have provided a link between 5-HT-associated colitis and MMPs.

Competing Interests

The authors declare that they have no conflict of interests.

Authors’ Contributions

Menglu Chen and Lei Gao are equal contributors to this study.


This study is supported by a Grant (no. 81370487 to Qiang Gao) from National Natural Science Foundation of China.


  1. A. Kaser, S. Zeissig, and R. S. Blumberg, “Inflammatory bowel disease,” Annual Review of Immunology, vol. 28, pp. 573–621, 2010. View at: Publisher Site | Google Scholar
  2. S. I. Grivennikov, “Inflammation and colorectal cancer: colitis-associated neoplasia,” Seminars in Immunopathology, vol. 35, no. 2, pp. 229–244, 2013. View at: Publisher Site | Google Scholar
  3. J. Terzić, S. Grivennikov, E. Karin, and M. Karin, “Inflammation and colon cancer,” Gastroenterology, vol. 138, no. 6, pp. 2101–2114.e5, 2010. View at: Publisher Site | Google Scholar
  4. K. L. Wallace, L.-B. Zheng, Y. Kanazawa, and D. Q. Shih, “Immunopathology of inflammatory bowel disease,” World Journal of Gastroenterology, vol. 20, no. 1, pp. 6–21, 2014. View at: Publisher Site | Google Scholar
  5. Y.-Z. Zhang and Y.-Y. Li, “Inflammatory bowel disease: pathogenesis,” World Journal of Gastroenterology, vol. 20, no. 1, pp. 91–99, 2014. View at: Publisher Site | Google Scholar
  6. D. J. Walther and M. Bader, “A unique central tryptophan hydroxylase isoform,” Biochemical Pharmacology, vol. 66, no. 9, pp. 1673–1680, 2003. View at: Publisher Site | Google Scholar
  7. G. Bertaccini, “Tissue 5-hydroxytryptamine and urinary 5-hydroxyindoleacetic acid after partial or total removal of the gastro-intestinal tract in the rat,” The Journal of Physiology, vol. 153, no. 2, pp. 239–249, 1960. View at: Publisher Site | Google Scholar
  8. M. D. Gershon, A. B. Drakontides, and L. L. Ross, “Serotonin: synthesis and release from the myenteric plexus of the mouse intestine,” Science, vol. 149, no. 3680, pp. 197–199, 1965. View at: Publisher Site | Google Scholar
  9. P. M. Whitaker-Azmitia, “The discovery of serotonin and its role in neuroscience,” Neuropsychopharmacology, vol. 21, supplement 2, pp. 2S–8S, 1999. View at: Publisher Site | Google Scholar
  10. G. M. Mawe and J. M. Hoffman, “Serotonin signalling in the gut-functions, dysfunctions and therapeutic targets,” Nature Reviews Gastroenterology and Hepatology, vol. 10, no. 8, pp. 473–486, 2013. View at: Publisher Site | Google Scholar
  11. R. Arreola, E. Becerril-Villanueva, C. Cruz-Fuentes et al., “Immunomodulatory effects mediated by serotonin,” Journal of Immunology Research, vol. 2015, Article ID 354957, 21 pages, 2015. View at: Publisher Site | Google Scholar
  12. P. R. Wade, J. Chen, B. Jaffe, I. S. Kassem, R. D. Blakely, and M. D. Gershon, “Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract,” The Journal of Neuroscience, vol. 16, no. 7, pp. 2352–2364, 1996. View at: Google Scholar
  13. D. Hoyer, J. P. Hannon, and G. R. Martin, “Molecular, pharmacological and functional diversity of 5-HT receptors,” Pharmacology Biochemistry and Behavior, vol. 71, no. 4, pp. 533–554, 2002. View at: Publisher Site | Google Scholar
  14. J. Hannon and D. Hoyer, “Molecular biology of 5-HT receptors,” Behavioural Brain Research, vol. 195, no. 1, pp. 198–213, 2008. View at: Publisher Site | Google Scholar
  15. M. D. Coates, C. R. Mahoney, D. R. Linden et al., “Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome,” Gastroenterology, vol. 126, no. 7, pp. 1657–1664, 2004. View at: Publisher Site | Google Scholar
  16. I. M. Minderhoud, B. Oldenburg, M. E. I. Schipper, J. J. M. ter Linde, and M. Samsom, “Serotonin synthesis and uptake in symptomatic patients with Crohn's disease in remission,” Clinical Gastroenterology and Hepatology, vol. 5, no. 6, pp. 714–720, 2007. View at: Publisher Site | Google Scholar
  17. I. I. Stoyanova and M. V. Gulubova, “Mast cells and inflammatory mediators in chronic ulcerative colitis,” Acta Histochemica, vol. 104, no. 2, pp. 185–192, 2002. View at: Publisher Site | Google Scholar
  18. C. P. Bearcroft, D. Perrett, and M. J. G. Farthing, “Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study,” Gut, vol. 42, no. 1, pp. 42–46, 1998. View at: Publisher Site | Google Scholar
  19. R. C. Spiller, D. Jenkins, J. P. Thornley et al., “Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome,” Gut, vol. 47, no. 6, pp. 804–811, 2000. View at: Publisher Site | Google Scholar
  20. M. El-Salhy, Å. Danielsson, R. Stenling, and L. Grimelius, “Colonic endocrine cells in inflammatory bowel disease,” Journal of Internal Medicine, vol. 242, no. 5, pp. 413–419, 1997. View at: Publisher Site | Google Scholar
  21. P. P. Bertrand, A. Barajas-Espinosa, S. Neshat, R. L. Bertrand, and A. E. Lomax, “Analysis of real-time serotonin (5-HT) availability during experimental colitis in mouse,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 298, no. 3, pp. G446–G455, 2010. View at: Publisher Site | Google Scholar
  22. S. C. Regmi, S.-Y. Park, S. K. Ku, and J.-A. Kim, “Serotonin regulates innate immune responses of colon epithelial cells through Nox2-derived reactive oxygen species,” Free Radical Biology and Medicine, vol. 69, pp. 377–389, 2014. View at: Publisher Site | Google Scholar
  23. J.-E. Ghia, N. Li, H. Wang et al., “Serotonin has a key role in pathogenesis of experimental colitis,” Gastroenterology, vol. 137, no. 5, pp. 1649–1660, 2009. View at: Publisher Site | Google Scholar
  24. R. Visse and H. Nagase, “Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry,” Circulation Research, vol. 92, no. 8, pp. 827–839, 2003. View at: Publisher Site | Google Scholar
  25. H. Nagaset and J. F. Woessner Jr., “Matrix metalloproteinases,” The Journal of Biological Chemistry, vol. 274, no. 31, pp. 21491–21494, 1999. View at: Publisher Site | Google Scholar
  26. T. Klein and R. Bischoff, “Physiology and pathophysiology of matrix metalloproteases,” Amino Acids, vol. 41, no. 2, pp. 271–290, 2011. View at: Publisher Site | Google Scholar
  27. R. P. Iyer, N. L. Patterson, G. B. Fields, and M. L. Lindsey, “The history of matrix metalloproteinases: milestones, myths, and misperceptions,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 303, no. 8, pp. H919–H930, 2012. View at: Publisher Site | Google Scholar
  28. S. S. Apte and W. C. Parks, “Metalloproteinases: a parade of functions in matrix biology and an outlook for the future,” Matrix Biology, vol. 44–46, pp. 1–6, 2015. View at: Publisher Site | Google Scholar
  29. K. Brew and H. Nagase, “The tissue inhibitors of metalloproteinases (TIMPs): an ancient family with structural and functional diversity,” Biochimica et Biophysica Acta (BBA)—Molecular Cell Research, vol. 1803, no. 1, pp. 55–71, 2010. View at: Publisher Site | Google Scholar
  30. G. Murphy, “Tissue inhibitors of metalloproteinases,” Genome Biology, vol. 12, no. 11, p. 233, 2011. View at: Publisher Site | Google Scholar
  31. Q. Gao, M. J. W. Meijer, F. J. G. M. Kubben et al., “Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases,” Digestive and Liver Disease, vol. 37, no. 8, pp. 584–592, 2005. View at: Publisher Site | Google Scholar
  32. C. Medina and M. W. Radomski, “Role of matrix metalloproteinases in intestinal inflammation,” Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 3, pp. 933–938, 2006. View at: Publisher Site | Google Scholar
  33. M. D. Baugh, M. J. Perry, A. P. Hollander et al., “Matrix metalloproteinase levels are elevated in inflammatory bowel disease,” Gastroenterology, vol. 117, no. 4, pp. 814–822, 1999. View at: Publisher Site | Google Scholar
  34. P. Garg, M. Vijay-Kumar, L. Wang, A. T. Gewirtz, D. Merlin, and S. V. Sitaraman, “Matrix metalloproteinase-9-mediated tissue injury overrides the protective effect of matrix metalloproteinase-2 during colitis,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 296, no. 2, pp. G175–G184, 2009. View at: Publisher Site | Google Scholar
  35. E. Hadler-Olsen, B. Fadnes, I. Sylte, L. Uhlin-Hansen, and J.-O. Winberg, “Regulation of matrix metalloproteinase activity in health and disease,” The FEBS Journal, vol. 278, no. 1, pp. 28–45, 2011. View at: Publisher Site | Google Scholar
  36. K. Warstat, T. Pap, G. Klein, S. Gay, and W. K. Aicher, “Co-activation of synovial fibroblasts by laminin-111 and transforming growth factor-β induces expression of matrix metalloproteinases 3 and 10 independently of nuclear factor-κB,” Annals of the Rheumatic Diseases, vol. 67, no. 4, pp. 559–562, 2008. View at: Publisher Site | Google Scholar
  37. H. Unoki, H. Bujo, M. Jiang, T. Kawamura, K. Murakami, and Y. Saito, “Macrophages regulate tumor necrosis factor-α expression in adipocytes through the secretion of matrix metalloproteinase-3,” International Journal of Obesity, vol. 32, no. 6, pp. 902–911, 2008. View at: Publisher Site | Google Scholar
  38. R. Hanemaaijer, P. Koolwijk, L. Le Clercq, W. J. A. De Vree, and V. W. M. Van Hinsbergh, “Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells: effects of tumour necrosis factor α, interleukin 1 and phorbol ester,” Biochemical Journal, vol. 296, no. 3, pp. 803–809, 1993. View at: Publisher Site | Google Scholar
  39. R. Blindt, F. Vogt, D. Lamby et al., “Characterization of differential gene expression in quiescent and invasive human arterial smooth muscle cells,” Journal of Vascular Research, vol. 39, no. 4, pp. 340–352, 2002. View at: Publisher Site | Google Scholar
  40. A. Kofla-Dlubacz, M. Matusiewicz, M. Krzystek-Korpacka, and B. Iwanczak, “Correlation of MMP-3 and MMP-9 with crohn's disease activity in children,” Digestive Diseases and Sciences, vol. 57, no. 3, pp. 706–712, 2012. View at: Publisher Site | Google Scholar
  41. S. O'Sullivan, J. F. Gilmer, and C. Medina, “Matrix metalloproteinases in inflammatory bowel disease: an update,” Mediators of Inflammation, vol. 2015, Article ID 964131, 19 pages, 2015. View at: Publisher Site | Google Scholar
  42. P. Kothari, R. Pestana, R. Mesraoua et al., “IL-6-mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages,” Journal of Immunology, vol. 192, no. 1, pp. 349–357, 2014. View at: Publisher Site | Google Scholar
  43. A. Li, S. Dubey, M. L. Varney, B. J. Dave, and R. K. Singh, “IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis,” The Journal of Immunology, vol. 170, no. 6, pp. 3369–3376, 2003. View at: Publisher Site | Google Scholar
  44. B. Chassaing, J. D. Aitken, M. Malleshappa, and M. Vijay-Kumar, “Dextran sulfate sodium (DSS)-induced colitis in mice,” Current Protocols in Immunology, vol. 104, Unit 15.25, 2014. View at: Publisher Site | Google Scholar
  45. D. K. Park and H.-J. Park, “Ethanol extract of Cordyceps militaris grown on germinated soybeans attenuates dextran-sodium-sulfate- (DSS-) induced colitis by suppressing the expression of matrix metalloproteinases and inflammatory mediators,” BioMed Research International, vol. 2013, Article ID 102918, 10 pages, 2013. View at: Publisher Site | Google Scholar
  46. K. Suzuki, X. Sun, M. Nagata et al., “Analysis of intestinal fibrosis in chronic colitis in mice induced by dextran sulfate sodium,” Pathology International, vol. 61, no. 4, pp. 228–238, 2011. View at: Publisher Site | Google Scholar
  47. F.-F. Chu, R. S. Esworthy, P. G. Chu et al., “Bacteria-induced intestinal cancer in mice with disrupted Gpx1 and Gpx2 genes,” Cancer Research, vol. 64, no. 3, pp. 962–968, 2004. View at: Publisher Site | Google Scholar
  48. A. Untergasser, I. Cutcutache, T. Koressaar et al., “Primer3-new capabilities and interfaces,” Nucleic Acids Research, vol. 40, no. 15, article e115, 2012. View at: Publisher Site | Google Scholar
  49. A. E. Bishop, R. Pietroletti, C. W. Taat, W. H. Brummelkamp, and J. M. Polak, “Increased populations of endocrine cells in Crohn's ileitis,” Virchows Archiv A: Pathological Anatomy and Histopathology, vol. 410, no. 5, pp. 391–396, 1987. View at: Publisher Site | Google Scholar
  50. A. Ahonen, K. Kyosola, and O. Penttila, “Enterochromaffin cells and macrophages in ulcerative colitis and irritable colon,” Annals of Clinical Research, vol. 8, no. 1, pp. 1–7, 1976. View at: Google Scholar
  51. P. J. O'Connell, X. Wang, M. Leon-Ponte, C. Griffiths, S. C. Pingle, and G. P. Ahern, “A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells,” Blood, vol. 107, no. 3, pp. 1010–1017, 2006. View at: Publisher Site | Google Scholar
  52. T. Dürk, E. Panther, T. Müller et al., “5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes,” International Immunology, vol. 17, no. 5, pp. 599–606, 2005. View at: Publisher Site | Google Scholar
  53. T. Müller, T. Dürk, B. Blumenthal et al., “5-hydroxytryptamine modulates migration, cytokine and chemokine release and T-cell priming capacity of dendritic cells in vitro and in vivo,” PLoS ONE, vol. 4, no. 7, Article ID e6453, 2009. View at: Publisher Site | Google Scholar
  54. A. M. Manicone and J. K. McGuire, “Matrix metalloproteinases as modulators of inflammation,” Seminars in Cell and Developmental Biology, vol. 19, no. 1, pp. 34–41, 2008. View at: Publisher Site | Google Scholar
  55. P. E. Van den Steen, P. Proost, A. Wuyts, J. Van Damme, and G. Opdenakker, “Neutrophil gelatinase B potentiates interleukin-8 tenfold by aminoterminal processing, whereas it degrades CTAP-III, PF-4, and GRO-α and leaves RANTES and MCP-2 intact,” Blood, vol. 96, no. 8, pp. 2673–2681, 2000. View at: Google Scholar
  56. G. Christoffersson, T. Waldén, M. Sandberg, G. Opdenakker, P.-O. Carlsson, and M. Phillipson, “Matrix metalloproteinase-9 is essential for physiological beta cell function and islet vascularization in adult mice,” American Journal of Pathology, vol. 185, no. 4, pp. 1094–1103, 2015. View at: Publisher Site | Google Scholar
  57. P. Garg, M. Rojas, A. Ravi et al., “Selective ablation of matrix metalloproteinase-2 exacerbates experimental colitis: contrasting role of gelatinases in the pathogenesis of colitis,” Journal of Immunology, vol. 177, no. 6, pp. 4103–4112, 2006. View at: Publisher Site | Google Scholar
  58. P. Nighot, R. Al-Sadi, M. Rawat, S. Guo, D. M. Watterson, and T. Ma, “Matrix metalloproteinase 9-induced increase in intestinal epithelial tight junction permeability contributes to the severity of experimental DSS colitis,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 309, no. 12, pp. G988–G997, 2015. View at: Publisher Site | Google Scholar
  59. M. de Bruyn, K. Machiels, J. Vandooren et al., “Infliximab restores the dysfunctional matrix remodeling protein and growth factor gene expression in patients with inflammatory bowel disease,” Inflammatory Bowel Diseases, vol. 20, no. 2, pp. 339–352, 2014. View at: Publisher Site | Google Scholar
  60. B. Von Lampe, B. Barthel, E.-O. Riecken, S. E. Coupland, and S. Rosewicz, “Differential expression of matrix metalloproteinases and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease,” Gut, vol. 47, no. 1, pp. 63–73, 2000. View at: Publisher Site | Google Scholar
  61. I. M. Clark, T. E. Swingler, C. L. Sampieri, and D. R. Edwards, “The regulation of matrix metalloproteinases and their inhibitors,” International Journal of Biochemistry and Cell Biology, vol. 40, no. 6-7, pp. 1362–1378, 2008. View at: Publisher Site | Google Scholar
  62. S. J. Crocker, A. Pagenstecher, and I. L. Campbell, “The TIMPs tango with MMPs and more in the central nervous system,” Journal of Neuroscience Research, vol. 75, no. 1, pp. 1–11, 2004. View at: Publisher Site | Google Scholar
  63. P. Devarajan, J. J. Johnston, S. S. Ginsberg, H. E. Van Wart, and N. Berliner, “Structure and expression of neutrophil gelatinase cDNA: identity with type IV collagenase from HT1080 cells,” Journal of Biological Chemistry, vol. 267, no. 35, pp. 25228–25232, 1992. View at: Google Scholar

Copyright © 2016 Menglu Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

1298 Views | 698 Downloads | 3 Citations
 PDF  Download Citation  Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly and safely as possible. Any author submitting a COVID-19 paper should notify us at to ensure their research is fast-tracked and made available on a preprint server as soon as possible. We will be providing unlimited waivers of publication charges for accepted articles related to COVID-19. Sign up here as a reviewer to help fast-track new submissions.